SynchNeuro is a Portfolio Company of Boomerang Ventures INDIANAPOLIS, IN / ACCESS Newswire / November 12, 2025 / Boomerang Ventures adds SynchNeuro, Inc. to its portfolio of seed-stage investments, ...
A large-scale study of more than 86,000 Europeans found that speaking multiple languages may help slow biological and ...
Using full genome sequencing data from more than 347,000 individuals, researchers quantified how much genetic differences explain human traits such as height, body mass index, fertility, and disease ...
NDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based on positive data from the ...
Using Large Action Model (LAM) trained on time-series data obtained from various customer touchpoints, such as online and ...
Researchers successfully developed a machine learning-based method for predicting symptom deterioration in patients with cancer.
IOP Publishing’s Machine Learning series is the world’s first open-access journal series dedicated to the application and ...
Q2 2026 Earnings Call November 12, 2025 4:00 AM ESTCompany ParticipantsSam GhezelbashSimon Michel - CEO & Member of ...
In addition, mHealth majorly involves the use of mobile and wireless technologies, which are deployed in monitoring and treatment of several acute and chronic disorders. Some of the other services, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback